Frontlight ResearchEarly access
Ovarian cancer trials in Spain
87 of 90 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Barcelona, Madrid, Málaga, Seville, Valencia
- Age
- 18 years and over
- People
- 890 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 2Taking peopleStatus of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial)
- Where
- Badalona, Barcelona, Córdoba, Girona, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Majadahonda, Palma, Sevilla, Valencia, Zaragoza
- Age
- 18 years and over
- People
- 100
- Run by
- Vall d'Hebron Institute of Oncology
See details and how to joinNCT06377267 · EU 2024-517363-24-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Where
- Barcelona, Córdoba, Girona, L'Hospitalet de Llobregat, Madrid, Valencia
- Age
- 18 years and over
- People
- 770 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00 - Phase 3Taking peopleA Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Where
- A Coruña, Barcelona, Córdoba, Girona, L'Hospitalet de Llobregat, Madrid, Valencia
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07318558 · EU 2023-508047-40-00 - Phase 3Taking peoplePhase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression
- Where
- Barcelona, Bilbao, Jaén, Madrid, Málaga, Vigo
- Age
- 18 years and over
- People
- 197 worldwide
- Run by
- K-Group Beta Inc.
See details and how to join2025-524641-27-00 - Phase 2Taking peopleRelacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- Where
- Badalona, Barcelona, Madrid, Valencia
- Age
- 18 years and over
- People
- 270 worldwide
- Run by
- Corcept Therapeutics
See details and how to joinNCT06906341 - Phase 3Not yet taking people in SpainStudy to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
- Where
- A Coruña, Badalona, Madrid, Málaga, Murcia, Palma, Sevilla, Vitoria
- Age
- 18 years and over
- People
- 544 worldwide
- Run by
- Genmab
See details and how to joinNCT07225270 · EU 2025-522167-15-00 - Phase 1/2Taking peopleA Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Valencia
- Age
- 18 years and over
- People
- 605 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06843447 · EU 2024-514674-47-00 - Phase 1Taking peopleAnti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 138 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07360314 · EU 2025-523232-39-00 - Phase 3Not yet taking people in SpainA Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
- Where
- Barcelona, Granada, Jaén, Jerez de la Frontera, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga, Pamplona, Pozuelo de Alarcón, San Sebastián de los Reyes, Sevilla, Vigo, Zaragoza
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT07791732 · EU 2025-522715-41-00 - Phase 1Taking peopleA Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Where
- Barcelona, Logroño, Madrid
- Age
- 18 years and over
- People
- 124 worldwide
- Run by
- Pliant Therapeutics, Inc.
See details and how to joinNCT06270706 - No phaseNot yet taking people in SpainAI-Assisted Remote Monitoring for Patients With or at Risk of Malignant Bowel Obstruction
- Where
- Madrid, Majadahonda
- Age
- 18 years and over
- People
- 140
- Run by
- Hospital Universitario 12 de Octubre
See details and how to joinNCT07931989 - Phase 1Not yet taking people in SpainA Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 156 worldwide
- Run by
- Context Therapeutics Inc.
See details and how to joinNCT06515613 · EU 2025-523968-20-00 - Phase 1Taking peopleA Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- Where
- Logrono, Madrid, Valencia
- Age
- 18 years and over
- People
- 150 worldwide
- Run by
- IDEAYA Biosciences
See details and how to joinNCT07503808 · EU 2026-526299-21-00 - Phase 1Not yet taking people in SpainA Study of LY4336619 in Adult Participants With Advanced Solid Tumors
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 370 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07928258 · EU 2026-526553-33-00 - Phase 3Taking peopleA Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Where
- Barcelona, Madrid, Málaga, Vigo
- Age
- 18 years and over
- People
- 420 worldwide
- Run by
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500 - Phase 3Not yet taking people in SpainTorvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
- Where
- Barcelona, Palma de Mallorca, Patraix
- Age
- 18 years and over
- People
- 950 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07851025 · EU 2026-526895-22-00 - Phase 1Taking peopleA Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Where
- Barcelona, Madrid, Valencia
- Age
- 18 years and over
- People
- 575 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00 - Phase 1SuspendedA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- L'Hospitalet de Llobregat, Madrid, Sevilla
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - Phase 2Taking peopleA Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Where
- Barcelona, Las Palmas, Madrid, Málaga, Pamplona, Valencia
- Age
- 18 years and over
- People
- 200 worldwide
- Run by
- Jazz Pharmaceuticals
See details and how to joinNCT06695845 · EU 2024-516551-41-00 - Phase 2Taking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid
- Age
- 18 years and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - Phase 3Taking peopleA Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Where
- Barcelona, Castellon, Granada, Madrid, Málaga, San Sebastián de los Reyes, Santiago de Compostela, Toledo
- Age
- 18 years and over
- People
- 1,630 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00 - Phase 3Not yet taking people in SpainStudy to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
- Where
- A Coruña, Badalona, Barcelona, Jaén, L'Hospitalet de Llobregat, Madrid, Majadahonda, Palma, Pamplona, Sabadell, Sevilla, Valencia
- Age
- 18 years and over
- People
- 688 worldwide
- Run by
- Genmab
See details and how to joinNCT07564141 · EU 2025-524202-15-00 - Phase 1/2Taking peopleFiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Where
- Barcelona, Girona, Huelva, Logrono, Madrid, Majadahonda, Pamplona, Pozuelo de Alarcón, Toledo
- Age
- 18 years and over
- People
- 334 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT06303505 · EU 2024-511074-80-01 - Phase 3Taking peopleA Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- Where
- Barcelona, Córdoba, Donostia, Madrid, Murcia, Santiago De Compostela, Valencia
- Age
- 18 years and over
- People
- 270 worldwide
- Run by
- Verastem, Inc.
See details and how to joinNCT06072781 · EU 2023-508204-38-00